Stability of trivalent human papillomavirus(types 16,18,58)recombinant vaccine(Escherichia coli)  

作　　者：Yu-Ying Liu Hai-Jiang Zhang Er-Cui Shen Dan Chen Yan Wang Si-Jia Fu Fei Yin Gui-Feng Zhang Yi-Guo Shen Yong-Jiang Liu 

机构地区：[1]Quality Department of Beijing Health Guard Biotechnology Inc.,BDA,Daxing District,Beijing 100176,China [2]National Key Laboratory of Biochemical Engineering,Institute of Process Engineering,Chinese Academy of Sciences,Beijing 100190,China [3]School of Chemical and Engineering,University of Chinese Academy of Sciences,Beijing 100049,China [4]Research and Development Department of Beijing Health Guard Biotechnology Inc.,BDA,Daxing District,Beijing 100176,China

出　　处：《Chinese Medical Journal》2021年第24期3020-3022,共3页中华医学杂志（英文版）

摘　　要：To the Editor:There are 530,000 new cases of cervical cancer and 270,000 deaths annually in the world,85%occur in developing countries.Among them,about 150,000 new cases of cervical cancer are in China each year,accounting for one-third of the total patients worldwide.[1]Vaccines are the most economical and effective ways of preventing infectious diseases.To stop the transmission of human papillomavirus(HPV)fundamentally,the most effective measure is to vaccinate safe and effective HPV vaccines.[2,3]Numerous studies have shown that vaccines based on HPV L1 virus-like particles(VLPs)have good safety and protective efficacy.[4]Infection of HPV16,HPV18,and HPV58 viruses is the main cause of cervical cancer in Chinese women.By preventing the infection of HPV16,HPV18,and HPV58 viruses,85.0%to 93.7%of cervical cancers can be prevented.[5].

关 键 词：PAPILLOMAVIRUS protective CERVICAL 

分 类 号：R392-33[医药卫生—免疫学]